Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC
Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Source: ajmc.com